Sydney M Crago

Christine Kay, MD, presents new findings on MCO-010, a novel optogenetic therapy improving vision in retinitis pigmentosa patients at the Retina Society meeting.

Hear highlights from the Vit-Buckle Society and its presence at EURETINA 2025.

ISTH0036 demonstrates potential to prevent fibrosis, reduce retinal fluid, and improve vision in AMD and diabetic macular edema patients.

EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research and fostering global networking among retina specialists.

Daniela Bacherini, MD, PhD, FEBO, said modern imaging modalities open up new possibilities in the peripheral retinal space.

Justis Ehlers discusses promising results from the HELIOS trial, revealing a novel treatment for diabetic retinopathy that may reduce treatment frequency.

The ultimate goal of redefining endpoints is enabling earlier diagnosis and treatment, said Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS

OCT-A angiography can help reveal early neurodegenerative disease signs, offering a noninvasive method for identifying high-risk patients through retinal analysis.

Neurotech Pharmaceuticals enhances its leadership by appointing Peter J. McDonnell, MD, a leading ophthalmology expert, to its Board of Directors.

identifeye HEALTH unveils a retinal screening platform, enhancing accessibility and efficiency in patient care through innovative technology and AI integration.

Research reveals a significant link between androgen exposure and central serous chorioretinopathy, aiding clinicians in assessing patient risk factors effectively.

Research reveals that GLP-1 medications, including semaglutide, do not increase diabetic retinopathy risks, offering reassurance for patients and prescribers.

Research reveals how neighborhood social factors impact patients with tractional retinal detachments, highlighting the need for improved access to care and support.

A look at podium presentations on GA research at ASRS 2025.

Franklin shares how methotrexate significantly reduces reoperation rates in diabetic patients with retinal detachments, enhancing postoperative outcomes and vision.

The DAVIO-2 study reveals EYP-1901's potential as a 6-month treatment for neovascular AMD, matching aflibercept's vision outcomes with fewer doses.

Matthew Starr, MD, discusses techniques for correcting astigmatism in patients lacking capsular support, enhancing visual outcomes surgery.

Lai spoke with Modern Retina about the study of PER-001, a novel therapeutic targeting the endothelin-1 receptor.